Company expands strategic focus into one of oncology’s most urgent supportive-care challenges Jericho, New York, April 02, 2026 (GLOBE NEWSWIRE) — Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a development-stage therapeutics company, today announced that it is expanding its drug development pipeline that encompassed six core indications: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease (“NAFLD”), and gout, by focusing on a new core indication: cancer cachexia, a serious cancer-associated wasting syndrome marked by progressive weight loss, muscle depletion, weakness and declining physical function. Cancer cachexia is widely recognized as one of the most serious complications in oncology and is estimated by the National Cancer Institute to occur in up to 80%...

New solution can reduce prescreen build times by up to 75% CHICAGO, April 02, 2026 (GLOBE NEWSWIRE) — With consumer credit originations expected to rise in 2026, lenders have a significant opportunity to drive growth through faster, more effective prescreen marketing campaigns. Yet many organizations struggle to execute these programs efficiently. A TransUnion-commissioned Forrester study found that 42% of financial services and insurance executives rely on basic segmentation, and nearly one-third lack meaningful personalization—even as consumers increasingly expect tailored experiences. To help lenders overcome these challenges, TransUnion has launched TruIQ Credit Strategy Studio. This self-service prescreen solution streamlines campaign development and activation, reducing prescreen build times by up to 75% and shrinking weeks-long...

Carla Goulart Peron, MD, Chief Medical Officer at Royal PhilipsCarla Goulart Peron, MD, Chief Medical Officer at Royal PhilipsApril 2, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that Carla Goulart Peron, MD, Chief Medical Officer at Philips, has been appointed to the Board of Directors of the Medical Device Innovation Consortium (MDIC). Founded in 2012, MDIC is a unique public-private partnership that brings stakeholders across the medical device spectrum together with the US Food and Drug Administration (FDA) and other agency partners to help ensure patient access to medical device innovations. “We are delighted to welcome Carla to MDIC’s Board of Directors,” said Andrew C. Fish, President and CEO of MDIC. “She brings deep experience bridging...

PUBLICIS GROUPE DISRUPTS SPORTS MARKETING LANDSCAPE WITH ACQUISITION OF 160OVER90 160over90 will be integrated with Publicis Sports and powered by the Groupe’s technology assets, Epsilon data, and scale in media to create the world’s premier data-driven sport & culture agency. April 2, 2026 – Paris – Publicis Groupe [Euronext Paris FR0000130577, CAC 40] announces it has entered into a definitive agreement to acquire 160over90, the premier global sports and culture-first agency. The move creates the industry’s leading global platform designed to drive measurable business outcomes by connecting brands to fans and audiences through unmatched technology, data, and scale across sport and culture. 160over90, a division of WME Group, is one of the largest global sports marketing and creative agencies that creates meaningful connections with...

Vancouver, British Columbia, April 02, 2026 (GLOBE NEWSWIRE) — NevGold Corp. (“NevGold” or the “Company”) (TSXV:NAU) (OTCQX:NAUFF) (Frankfurt:5E50) is pleased to announce further metallurgical testwork results on the residual tailings material from the positive Phase II antimony (“Antimony”, “Sb”) testwork included in the November 5, 2025 News Release. The residual tailings material from the antimony leaching process had remaining gold mineralization, and went through a second sequential stage of leaching testwork focused on gold. The positive sequential antimony and gold leaching results highlight the exceptional geo-metallurgical characteristics of the oxide antimony-gold Limousine Butte Project (the “Project”, “Limo Butte”) in Nevada, one of the world’s prolific mining jurisdictions. As the Company has stated in previous News...

VANCOUVER, British Columbia, April 02, 2026 (GLOBE NEWSWIRE) — Yukon Metals Corp. (CSE: YMC, FSE: E770, OTCQB: YMMCF) (“Yukon Metals” or the “Company”) is pleased to report results from a successful 2025 diamond drilling program at the Star River property (“Star River” or the “Property”) located adjacent to the past-producing Ketza mine in the southern Yukon, motivating the acquisition of additional, highly prospective, Stump claims along the same structural corridor. The 2025 drill campaign focused on testing the down-dip and along-strike extensions of gold and silver-bearing veins exposed at surface within the F2, F3 and Saddle zones. Holes successfully correlated geology with geophysical surveys, including electromagnetics, gravimetry and drone magnetics defining a 1-kilometre-long structural mineralized corridor containing multiple...

NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced that an abstract featuring its investigational iNKT cell therapy, agenT-797, has been accepted for presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place May 11-15, 2026, in Boston, MA. Presentation Details:Abstract Title: AgenT-797 Allogeneic iNKT Cell Therapy Demonstrates Adaptive Immune Modulation in Cancer and ARDS Presenter: Terese C. Hammond, MD; Program Director of Pulmonary and Critical Care, Kaweah Health Medical Center; Head of Inflammatory and Pulmonary Diseases, MiNK TherapeuticsAdditional...

MALVERN, Pa., April 02, 2026 (GLOBE NEWSWIRE) — Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the issuance of U.S. Patent No. 12,582,632 B2, covering prevention and treatment of neurological injuries arising from brain infections through the administration of buntanetap or related compounds. The role of infectious agents in the development of AD has gained significant scientific attention in recent years. Research emerging from the brain microbiome studies has demonstrated that viral, bacterial, fungal, protozoan, or parasitic infections may lie at the heart of Alzheimer’s pathology. Established...

Campaign to test extension of pegmatite system and evaluatepotential for niobium and rare earths Vancouver, British Columbia, April 02, 2026 (GLOBE NEWSWIRE) — Drills are turning for the first time at North American Niobium and Critical Minerals Corp.’s (CSE: NIOB) (FSE: KS82.F) (OTCQB: NIOMF) (North American Niobium or the Company) Seigneurie Project. “The team has wasted no time. We announced receipt of the key authorization last week, and the drill is already running this week. This first phase is designed to test the extension of the pegmatite system and evaluate its potential to host niobium and rare earth mineralization,” said Murray Nye, North American Niobium’s Chief Executive Officer. “The results will help guide the next stage of exploration at Seigneurie.” HighlightsDiamond drilling has commenced at the 100%-owned Seigneurie...

HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) — CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), today announces a new payer coverage agreement with Highmark, effective April 1, 2026, providing reimbursement for its CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay for patients with metastatic central nervous system cancers. Highmark joins a growing list of national and regional payers, including United Healthcare and Humana, that provide coverage for CNSide. The addition of Highmark expands CNSide’s total covered lives from approximately 67 million to 75 million, representing continued progress toward the Company’s 2026 objective of 150 million covered lives, while expanding patient access across the U.S. The agreement is expected to further accelerate...